ARCHIVES

Research Program For Biological Response Modifiers Outlined By DCT board Subcommittee

This article is from The Cancer Letter archive.

Vol. 05 No. 46 | November 16, 1979

Download PDF Visit The Full Archive

Related Articles

Retrospective Data Clean-up Can’t Help C225 Phase II Trial; Protocol Far Too “Fuzzy”

March 8, 2002

Former NIH Director Varmus calls for more oversight of conflicts, expresses surprise at growth of Title 42 program.

May 21, 2004

In Brief: Mary-Claire King Named Disney Professor By Cancer Society; Date Corrected In Article

July 1, 1994

Colorado Researchers Study Massage To Reduce Symptoms

September 26, 2003

Xeloda-Eloxatin Study Updated; Phase III Trial Interim Analysis

December 27, 2002

Too Few Minority Scientists Enter Careers In Public Health, Oncology, Bynum Reports

March 24, 1989